Fresenius Medical Care AG & Co. KGaA cuts outlook for FY 2022 due to increased headwinds from U.S. labor market situation and global inflation, and withdraws 2025 targets
|
DGAP-Ad-hoc: Fresenius Medical Care AG & Co. KGaA / Key word(s): Change in Forecast/Preliminary Results
In the second quarter Fresenius Medical Care experienced increasing different headwinds that are now expected to negatively impact the Company´s earnings development in the second half of FY 2022 to a significant larger degree than anticipated when giving guidance. Earnings development in particular is anticipated to be affected by increased wage inflation and worsened staff shortages resulting in capacity constraints in North American Health Care Services. Additionally, the worsening of the macroeconomic environment is expected to result in higher inflation and disruptions in supply chain.
Against this backdrop, Fresenius Medical Care now anticipates for FY 2022, in constant currency and before special items, revenue to grow at the low end of the previously guided low to mid-single digit percentage range and now assumes net income (attributable to shareholders of Fresenius Medical Care AG & Co. KGaA) to decline around a high teens percentage range. Due to uncertainties of the U.S. labor market and macro-economic inflationary environment, which are assumed to be temporary, Fresenius Medical Care withdraws 2025 targets of compounded annual average increases in the mid-single-digit percentage range for revenue and in the high-single-digit percentage range for net income (attributable to shareholders of Fresenius Medical Care AG & Co. KGaA). Contact: Dr. Dominik Heger EVP | Head of Investor Relations, Strategic Development & Communications dominik.heger@fmc-ag.com P. +49 6172 609 2601
27-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Fresenius Medical Care AG & Co. KGaA |
| Else-Kröner-Straße 1 | |
| 61352 Bad Homburg | |
| Germany | |
| Phone: | +49 (0) 6172- 609 2525 |
| Fax: | +49 (0) 6172- 609 2301 |
| E-mail: | ir@fmc-ag.com |
| Internet: | www.freseniusmedicalcare.com |
| ISIN: | DE0005785802 |
| WKN: | 578580 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange |
| EQS News ID: | 1407557 |
| End of Announcement | DGAP News Service |
|
|
1407557 27-Jul-2022 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.